A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.
Richard D. Kim(Moffitt Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Sara Ferrando‐Martínez(National Institutes of Health), Hirva Mamdani(Wayne State University), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Melissa L. Johnson(Tennessee Oncology), Julie A. Murphy, Lauren Trogun, Byung Ha Lee(OncoImmune (United States)), Se Hwan Yang, Minal Barve(Mary Crowley Cancer Research Center)
Cited by 3
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373